The agency seeks projects that evaluate and improve healthcare data used by AI and accelerate the use of health IT products among mental healthcare providers.
ONC provides grants for AI, behavioral health projects Read More »
Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership Read More »
Intensity Therapeutics, Inc. announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024.
DarioHealth Corp., a leader in the global digital health market, reported financial results for the first quarter 2024.
DarioHealth Reports First Quarter 2024 Financial and Operating Results Read More »
BioAge Labs, Inc. today announced the formation of its Scientific Advisory Board (SAB).
The company behind the hormone-free contraceptive Phexxi®, Evofem Biosciences, Inc. announced financial results for the first quarter of 2024.
Evofem Biosciences Announces Financial Results for the First Quarter of 2024 Read More »
La enuresis nocturna, comúnmente conocida como mojar la cama, es un problema que afecta a millones de niños y adolescentes en todo el mundo. Esta condición, caracterizada por la pérdida involuntaria de orina durante el sueño, puede ser motivo de angustia y verg&uum …
Enuresis nocturna: Causas, tratamientos y estrategias efectivas para prevenirla Read More »
Una herramienta moderna ilumina los misterios del pasado de una manera nunca antes imaginada: las pruebas genéticas. En un mundo donde las líneas familiares pueden desdibujarse por el tiempo y la migración, estas pruebas ofrecen una ventana única hacia nuestro legado ance …
El auge de las pruebas genéticas en la genealogía Read More »
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company’s lead asset in non-opioid acute pain management.
Ryvu Therapeutics, a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported financial results for the first quarter, ended March 31, 2024, and provided a corporate update.
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update Read More »
